Dijon, France

Luc L Lebreton


Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 7(Granted Patents)


Location History:

  • Maisons Laffitte, FR (1992 - 1993)
  • Dijon, FR (1993 - 1994)

Company Filing History:


Years Active: 1992-1994

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Luc L Lebreton: Innovator in Pharmaceutical Chemistry

Introduction

Luc L Lebreton is a notable inventor based in Dijon, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds. With a total of four patents to his name, Lebreton's work focuses on therapeutic agents that have the potential to impact medical treatments.

Latest Patents

Lebreton's latest patents include derivatives of 4-(hetero)arylmethyloxy phenyl diazole. These derivatives are characterized by a specific formula where R1 represents a C1-C4 alkyl group, and Ar is an aryl or heteroaryl group. The compounds are designed to inhibit type B monoamine oxidase, which is crucial in various therapeutic applications. The detailed structure of these derivatives includes various substituents, such as halogen atoms, CN, NO2, CF3 groups, and alkyl or alkoxy groups, making them versatile in their potential uses.

Career Highlights

Luc L Lebreton has had a distinguished career, working with Delalande S.A., where he has been able to apply his expertise in chemistry to develop innovative solutions. His work has not only advanced the field but has also contributed to the company's reputation as a leader in pharmaceutical research.

Collaborations

Throughout his career, Lebreton has collaborated with esteemed colleagues, including Rene L Milcent and Fathi Mazouz. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Luc L Lebreton's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…